quinocarcin (D 52)

from Streptomyces melanovinaceus nov.sp.; structure given in second source

Also Known As:

D 52; D-52; KW 2152; KW-2152; isoquinocarcin; quinocarmycin; quinocarmycin citrate; 3,6-Imino-1H-2-oxa-11c-azanaphth(1,2,3-cd)azulene-5-carboxylic acid, 2a,3,4,5,6,6a,7,11b-octahydro-11-methoxy-12-methyl-, (2aalpha,3alpha,5alpha,6alpha,6aalpha,11balpha)-(-)-

Networked: 25 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - quinocarcin: 25

Experts

1.	Boeing, Heiner: 1 article (08/2019)
2.	De Henauw, Stefaan: 1 article (08/2019)
3.	Devleesschauwer, Brecht: 1 article (08/2019)
4.	Hoffmann, Georg: 1 article (08/2019)
5.	Iqbal, Khalid: 1 article (08/2019)
6.	Knüppel, Sven: 1 article (08/2019)
7.	Michels, Nathalie: 1 article (08/2019)
8.	Schwedhelm, Carolina: 1 article (08/2019)
9.	Schwingshackl, Lukas: 1 article (08/2019)
10.	Blanchard, Chris M: 1 article (01/2017)

Related Diseases

1.	Neoplasms (Cancer) 12/01/1988 - "Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice." 09/01/1987 - "The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for quinocarmycin at 0.1 and 1.0 microgram/ml continuous exposure was 42% and 72%, respectively, which was superior to that of other drugs. " 03/01/1987 - "KW-2152 displayed significant antitumor activities against the human tumor xenografts in 3 out of 13 strains (23.1 per cent) at the schedule of q4d X 3, with a daily dose of 7.3 mg/kg. Depending on the schedule of administration, tumor activity was observed in 8 out of 13 strains (61.5 per cent) at a schedule of q2d X 6, with a daily dose of 7.3 mg/kg. SH-2 and SH-9 gastric tumors were sensitive to KW-2152 and growth was completely inhibited with the schedule of q4d X 3, and a daily dose of 7.3 mg/kg. Thus, KW-2152 seems to have a wide antitumor spectrum, and the possible antitumor effects for clinical use, warrant attention." 03/01/1987 - "The antitumor activities of KW-2152, a new isoquinon derivative, were examined in thirteen human tumor xenografts, transplanted into nude mice. " 03/01/1987 - "Antitumor activities of KW-2152, a new isoquinon agent, against human tumor xenografts transplanted into nude mice."
2.	Leukemia P388 03/15/1987 - "A novel antitumor antibiotic, 2a,3,4,5,6,6a,7,11b-octahydro-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11 c- azanaphth(1,2,3-cd)azulene-5-carboxylic acid monocitrate (quinocarmycin citrate; KW2152) was selected for investigation in a number of experimental tumor systems because of its efficacy against P388 leukemia. "
3.	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 07/01/1998 - "The impact of psychotherapy on PTSD and psychiatric symptomatology was significant, d = .52, r = .25, when measured immediately after treatments were administered. " 01/01/2016 - "Lower levels of pretreatment PTSD, depression, and anxiety symptoms and fewer trauma types were related to child- and parent-reported responder status (d = .57, d = .52, respectively). "
4.	Pain (Aches) 01/01/2017 - "UCAN had significant negative effects on self-efficacy (-.7; 95% CI = -1.2 to -.1; d = -.53, p = .019), affective attitude (-.4; 95% CI = -.8 to -.0; d = -.45, p = .044), instrumental attitude (-.5; 95% CI = -.9 to -.1; d = -.43, p = .026) and confidence to perform PA in bad weather (-.8; 95% CI = -1.6 to -.1; d = -.49, p = .030), despite health issues (-.7; 95% CI = -1.3 to -.1; d = -.48, p = .031), despite pain/soreness (-.7; 95% CI = -1.4 to -.1; d = -.52, p = .020), despite family responsibilities (-1.0; 95% CI = -1.7 to -.3; d = -.62, p = .005) and when PA is boring (-.8; 95% CI = -1.4 to -.1; d = -.54, p = .016). " 01/01/2013 - "Smokers reported significantly less self-control over pain (d = .66), lower general activity levels (d = .52), more fatigue (d = .80), and poorer sleep quality (d = .53) than non-smokers. "
5.	Melanoma (Melanoma, Malignant) 02/15/1995 - "Quinocarmycin monicitrate (KW2152) and its analogue, DX-52-1, demonstrated specificity for melanomas in the National Cancer Institute in vitro human tumor cell line drug screen. " 09/04/1998 - "The hydrocyanated derivative of the antitumor antibiotic quinocarmycin, DX-52-1 (I), exhibits impressive activity against human melanoma xenograft models in vivo. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	Acids
3.	DX 52-1
4.	D 53
5.	Ghrelin
6.	Superoxide Dismutase
7.	Gold
8.	DNA (Deoxyribonucleic Acid)
9.	tetrazomine
10.	naphthyridinomycin

Related Therapies and Procedures

1.	Laser In Situ Keratomileusis (LASIK)
2.	Intramuscular Injections
3.	Aftercare (After-Treatment)